Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Sequenom may be done....

April 30, 2009

Analysis of:UPDATE 2-Sequenom delays Down Syndrome test; shares plunge | uk.reuters.com

Sequenom had only one application in its near market pipeline and it appears that it may never make it to a doctor's office. The basis for its use was shaky in my analysis and this reflects to me that the bottom for its market cap may not yet have been reached.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS